Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 8/20 | 0.51 |
| ▸ | FNTB | P49356 | 8/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL7701815 | 0.96 | FNTA (0.49) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6868055 | 0.86 | FNTA (0.63) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6872833 | 0.82 | FNTA (0.49) | FNTAFNTBCYP1A2CYP3A4CNR1 | |
| SCHEMBL6869864 | 0.82 | FNTA (0.49) | FNTAFNTBCYP1A2CYP3A4CNR1 | |
| SCHEMBL8473920 | 0.80 | FNTA (0.50) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6867606 | 0.79 | FNTA (0.67) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6869798 | 0.79 | FNTA (0.61) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6861981 | 0.75 | ALDH1A1 (0.42) | FNTAFNTBCYP1A2CYP3A4CNR1 | |
| SCHEMBL4156125 | 0.75 | FNTA (0.85) | FNTAFNTBCYP19A1CYP1A2CYP3A4 | |
| SCHEMBL6169572 | 0.75 | FNTA (0.53) | FNTAFNTBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809265-A4 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1809265-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2007-07-25 | — | — | EP | claimed |
| WO-2005089504-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1106610-B1 | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-16 | — | — | EP | claimed |
| CN-1101391-C | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-12 | — | — | CN | claimed |
| EP-1019395-B1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-30 | — | — | EP | claimed |
| EP-1106610-A1 | Farnesyl transferase inhibiting 2-quinolone derivatives | Janssen Pharmaceutica N.V. (BE) | 2001-06-13 | — | — | EP | claimed |
| US-5968952-A | ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-10-19 | — | — | US | claimed |
| CN-1200732-A | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1998-12-02 | — | — | CN | claimed |
| EP-1106610-B1 | Farnesyl transferase inhibiting 2-quinolone derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-16 | — | — | EP | disclosed |
| EP-1019395-B1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-30 | — | — | EP | disclosed |
| EP-1106610-A1 | Farnesyl transferase inhibiting 2-quinolone derivatives | Janssen Pharmaceutica N.V. (BE) | 2001-06-13 | — | — | EP | disclosed |
| EP-1019395-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | disclosed |
| US-5968952-A | ANTITUMOR AGENTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 1999-10-19 | — | — | US | disclosed |
| WO-1997016443-A1 | FARNESYL TRANSFERASE INHIBITING 2-QUINOLONE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-05-09 | — | — | WO | disclosed |